Australian biotech market watch 19/06/09
Friday, 19 June, 2009
The All Ordinaries has had a turbulent week, shedding some of the gains made in the previous seven days, although Friday was mainly level, with the All Ords sitting at 3190 at 4:15pm on Friday.
Contrasting the flagging performance of the All Ordinaries, the health indices are up on Friday nearly 1.5% from last week.
CSL (ASX:CSL), the smallest of the six big vaccine makers worldwide, is pipped to have a swine flu vaccine first, and this optimism has resulted in some lifts in CSL's share price over the last few weeks. Today it's up 42c to $31.55.
Cochlear (ASX:COH) has gone through a few wobbles this week, finishing on $56.84, only a few cents off its start on Monday of $56.92.
Amongst the losers is Ansell (ASX:ANN), down 1.6% to $8.80, and Blackmores (ASX:BKL), dropping 4.7% after riding high on the threats from swine flu, which appear to be subsiding with the federal government reducing the alert level on Wednesday.
Novogen (ASX:NRT) has also slipped another 13% today to 62c, down a full 40% from its peak on May 19 of $1.02.
Ramsay Health Care has seen a slight slide over the last couple of days down to $11.07.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
